March 16, 2022 – Rinvoq® (upadacitinib), made by AbbVie, has a new indication to treatment moderately to severely active ulcerative colitis in adults who have had an inadequate response or intolerance to at least one tumor necrosis factor blocker.

• Recommended dosing under the new indication is 45mg once daily for eight weeks, followed by maintenance dosing of 15mg once daily. For patients who have refractory, severe, or extensive disease, a dose of 30mg once daily can be considered. Rinvoq should be used at the lowest effective dose to maintain response and should be discontinued if an adequate therapeutic response is not achieved at the 30mg dosage.
• First FDA approved in 2019, Rinvoq is also indicated to treat rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.